KDR and renal cell carcinoma: In a similar manner, the use of mice xenografts of human renal cell carcinoma revealed that pharmacological PERK inhibition by compound HC-5404 enhanced the antiangiogenic effects of vascular endothelial growth factor (VEGF) receptor (VEGFR) inhibitors, resulting in further decreased blood vessel density and improved tumor regression [142].